

# Program

## WEDNESDAY JUNE 8, 2022

16:00 – 17:00	Registration
<b>Session 1: How to diagnose NAFLD/NASH today?</b>	
<i>Chairs: Ger Koek &amp; Sven Francque</i>	
17.00	Opening and welcome
17.00-17.20	<i>What is the role of genetic testing in NAFLD?</i> <b>Stefano Romeo</b> ; University of Gothenburg, Sweden
17.20-17.40	<i>MicroRNAs as biomarkers: scientific plausibility and pathophysiological role</i> <b>Rui Eduardo Castro</b> ; University of Lisbon, Portugal
17.40-18.00	<i>Non-invasive diagnostic tests for NASH: how to assess their accuracy in diagnosis and follow-up?</i> <b>Jerome Boursier</b> ; CHU Angers, France
18.00-18.20	<i>NAFLD-NASH and the heart</i> <b>Onno Holleboom</b> ; Amsterdam UMC, The Netherlands
18.20-18.40	<i>Referral pathways for patients with NAFLD</i> <b>Manolis Tsciohatzis</b> ; UCL Institute for Liver & Digestive Health, UK
18.40-19.00	Panel discussion

## THURSDAY JUNE 9, 2022

08.00-08.30	Registration
08.30-08.35	Opening by the chairs
<b>Session 2: Metabolic regulation and insulin resistance in NAFLD</b> <i>Chairs: Ronit Shiri-Sverdlov &amp; Bart Staels</i>	
08.35-09.00	<i>Glucose sensing and lipid metabolism in NAFLD</i> <b>Catherine Postic</b> ; Institut Cochin, France
09.00-09.15	<i>Abstract 1: Investigating microRNAs to explain the link between cholesterol metabolism and NAFLD in humans: a systematic review</i> <b>Maurice Konings</b> ; Maastricht University, The Netherlands
09.15-09.30	<i>Abstract 2: A common variant in the ketohexokinase gene is associated with fructosuria and cardiometabolic outcomes</i> <b>Ameé Buziau</b> ; Maastricht University, The Netherlands
09.30-10.00	<i>Insulin resistance &amp; NAFLD</i> <b>Amalia Gastaldelli</b> ; Institute of Clinical Physiology (IFC) of CNR of Pisa, Italy
10.00-10.15	<i>Abstract 3: Regulation of GDF-15 in obesity, type 2 diabetes and NAFLD</i> <b>Laurent L'homme</b> ; UMR1011 INSERM, Institut Pasteur de Lille, Univ. Lille, France
10.15-10.30	<i>Abstract 4: The role of the hepatokine fetuin B in glucose homeostasis and adipose tissue function</i> <b>Kenneth Pasmans</b> ; Maastricht University, The Netherlands
<u>10.30-11.00</u>	<u>Break &amp; visiting exhibitions</u>
<b>Session 3: Inflammation and immune mechanisms in NAFLD</b> <i>Chairs: Luisa Vonghia &amp; Leen Heyens</i>	
11.00-11.30	<i>deLIVERing a spatial cell atlas of the healthy and obese liver across species</i> <b>Charlotte Scott</b> ; VIB-UGent Center for Inflammation Research, Belgium
11.30-11.45	<i>Abstract 5: Human hepatic in vitro models identify ANGPTL4, PDK4 and PLIN2 as potential pro-steatogenic mediators induced by elafibranor</i> <b>Joost Boeckmans</b> ; Vrije Universiteit Brussel, Belgium
11.45-12.00	<i>Abstract 6: FAT10 in the senescence of hepatocytes and NASH development</i> <b>Lucie Bernard</b> ; UMR1011 INSERM, Institut Pasteur de Lille, Univ. Lille, France
12.00-12.30	<i>NAFLD, immune cells and HCC</i> <b>Mathias Heikenwälder</b> ; Deutsches Krebsforschungszentrum, Germany

## THURSDAY JUNE 9, 2022

12.30-12.45	Abstract 7: <i>Characterization of hepatic parenchymal hypoxia in a mouse model of nonalcoholic steatohepatitis</i> <b>Cédric Peleman</b> ; University of Antwerp, Belgium
12.45-13.00	Abstract 8: <i>Investigating cDC involvement in the pathogenesis of non-alcoholic fatty liver disease</i> <b>Kathryn Waller</b> ; Vlaams instituut Biotechnologie UGent, Belgium
<u>13.00-14.00</u>	<u>Lunch &amp; visiting exhibitions</u>
<b>Short abstract presentations</b>	
14.00-14.05	Abstract 15: <i>Involvement of the alteration of the biological clock in the development of non-alcoholic fatty liver disease (NAFLD)</i> <b>Aurore Hebras</b> ; UMR1011 INSERM, Univ.Lille, France
14.05-14.10	Abstract 24: <i>The progression of NASH to hepatocellular carcinoma is influenced by extracellular Cathepsins</i> <b>Hester van Mourik</b> ; Maastricht University, The Netherlands
14.10-14.15	Abstract 22: <i>Hypoxia marker pimonidazole displays panlobular positivity in nonalcoholic Steatohepatitis</i> <b>Cédric Peleman</b> ; University of Antwerp, Belgium
14.15-14.20	Abstract 17: <i>Liraglutide reduces hepatosteatosis in NAFLD and drug-induced fatty liver cell culture models through PPAR<math>\gamma</math> signaling pathway</i> <b>Martina Smolic</b> ; University of Oijek, Croatia
14.20-14.25	Abstract 23: <i>Metabolic-associated fatty liver disease in Turkish individuals living in and outside of Turkey: a shared burden at different locations?</i> <b>Irem-Seray Gürtekin</b> ; Maastricht University, The Netherlands
14.25-14.30	Abstract 25: <i>Pneumococcal immunization against oxLDL decreases tumor burden in NASH-derived hepatocellular carcinoma</i> <b>Lara Stoffels</b> ; Maastricht University, The Netherlands
<b>Session 4: Inter-organ crosstalk in NAFLD/NASH</b> <i>Chairs: Rui Eduardo Castro &amp; Patrick Rensen</i>	
14.30-15.00	<i>Adipose-liver crosstalk in NAFLD</i> <b>Patrick Rensen</b> ; Leiden University, The Netherlands
15.00-15.15	Abstract 9: <i>Changes of non-invasive tests for liver steatosis and fibrosis by dual PPAR<math>\alpha</math>/g agonism in T2DM and coronary artery disease - Post-hoc analysis of the AleCardio RCT</i> <b>Vivian de Jong</b> ; Julius Center, UMC Utrecht, The Netherlands
15.15-15.45	<i>Gut-Liver Axis and Microbiota</i> <b>Nathalie Delzenne</b> ; Louvain Drug Research Institute (LDRI) – UCLouvain, Belgium

## THURSDAY JUNE 9, 2022

15.45-16.00	<p>Abstract 10: <i>Effect of bile acids on CD-1d-restricted antigen presentation to NKT cells</i>  <b>Valentine Guinot</b>; UMR1011 INSERM, Institut Pasteur de Lille, Univ. Lille, France</p>
16.00-16.30	<p><i>Clock perturbations as a common contributor to NAFLD, dyslipidemia and atherosclerosis</i>  <b>Helene Duez</b>; UMR1011 INSERM, Institut Pasteur de Lille, France</p>
<u>16.30-17.00</u>	<u>Break &amp; visiting exhibitions</u>
<p><b>Session 5: Complications of NAFLD/NASH</b>  <i>Chairs: Nicolas Lanthier &amp; Ger Koek</i></p>	
17.00-17.30	<p><i>Modeling fibrosis and NAFLD in 3D liver cultures</i>  <b>Leo van Grunsven</b>; Vrije Universiteit Brussel, Belgium</p>
17.30-18.00	<p><i>Transcriptional control of hepatic stellate activation in liver fibrosis by BNC2</i>  <b>Jerome Eeckhoute</b>; CR CNRS, INSERM UMR1011, France</p>
18.00-18.30	Panel discussion
<u>19.00- 23.00</u>	<u>Networking event with dinner at the hotel restaurant 'de Mangerie' (only for registered participants)</u>

## FRIDAY JUNE 10, 2022 – NASH AWARENESS DAY

08:25-08:30	Opening
<b>Session 6: When and how should NAFLD/NASH be treated?</b>	
<i>Chairs: Onno Holleboom &amp; Leen Heyens</i>	
08.30-09.00	<i>Update on medical treatment for NAFLD and future perspective</i> <b>Sven Francque</b> ; University of Antwerp, Belgium
09.00-09.15	Abstract 11: <i>Resmetirom reduces lipid load, restores THRB expression and prevents cell damage in a human stem cell based in vitro MAFLD model</i> <b>Alexandra Gatzios</b> ; Vrije Universiteit Brussel, Belgium
09.15-09.45	<i>Lifestyle interventions in NAFLD: What should we aim to achieve in the clinical setting</i> <b>Kate Hallsworth</b> ; NIHR Newcastle Biomedical Research Centre, UK
09.45-10.00	Abstract 12: <i>Run for your live(r): Exercise training at different times of day differentially modulates hepatic inflammation in early NAFLD</i> <b>Milena Schönke</b> ; LUMC; The Netherlands
<u>10.00-10.30</u>	<u>Break &amp; visiting exhibitions</u>
10.30-11.00	<i>How should the extrahepatic co-morbidities be treated?</i> <b>Raluka Pais</b> ; Pitié-Salpêtrière Hospital, France
11.00-11.15	Abstract 13: <i>NAFLD and cardiometabolic health: Importance of visceral obesity and cardiorespiratory fitness</i> <b>Dominic Chartrand</b> ; Université Laval, Canada
11.15-11.45	<i>Role of bariatric surgery in NAFLD</i> <b>François Pattou</b> ; University Hospital Lille, France
<b>Short abstract presentations</b>	
11.45-11.50	Abstract 19: <i>Relationship between non-alcoholic fatty liver disease and coronary artery disease: A Mendelian randomization study</i> <b>Zhewen Ren</b> ; Maastricht University, The Netherlands
11.50-11.55	Abstract 18: <i>Evaluation of liver fibrosis using the Fibroscan™ in the bariatric workup: recommendations for clinical practice</i> <b>Willy Theel</b> ; Franciscus Gasthuis, The Netherlands
11.55-12.00	Abstract 20: <i>Getting GRIP on NASH: Implementation of an International Transmural Screening Program</i> <b>Vivian de Jong</b> ; Julius Center, UMC Utrecht, The Netherlands
12.00-12.05	Abstract 16: <i>Deep phenotyping of high intensity interval training in patients with advanced stages of NAFLD</i> <b>Veera Houttu</b> ; Amsterdam UMC, The Netherlands

## FRIDAY JUNE 10, 2022 – NASH AWARENESS DAY

12.05-12.10	<p>Abstract 14: <i>The Fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients</i>  <b>Leen Heyens</b>; Maastricht University, The Netherlands &amp; Hasselt University, Belgium</p>
12.10-12.15	<p>Abstract 21: <i>Reduced handgrip strength is correlated with a higher FLI in NAFLD patients with type 2 diabetes and obesity</i>  <b>Leen Heyens</b>; Maastricht University, The Netherlands &amp; Hasselt University, Belgium</p>
<u>12.15-12.45</u>	<u>Lunch &amp; visiting exhibitions</u>
<p><b>Session 7: NAFLD awareness</b>  <i>Chairs: Ger Koek &amp; Achim Kautz</i></p>	
12.45-12.55	<p><i>Burden of NAFLD in Europe, and health care costs</i>  <b>Ger Koek</b>; Maastricht University Medical Center, The Netherlands</p>
12.55-13.10	<p><i>Experience of a NAFLD patient</i></p>
13.10-13.30	<p><i>What is the role of patient advocacy groups in improving NAFLD awareness and how can the patient guideline help?</i>  <b>Achim Kautz</b>; Deutsche Leberhilfe e.V., Germany</p>
13.30-13.50	<p><i>Why and how to identify NAFLD in primary care: opportunities and challenges</i>  <b>Christos Lionis</b>; University of Crete, Greece  <b>Jean Muris</b>; Maastricht University, The Netherlands</p>
13.50-14.10	<p><i>How can the food industry help to prevent NAFLD and associated diseases?</i>  <b>Robert-Jan Koens</b>; Jumbo Supermarkten, The Netherlands</p>
14.10-14.30	<p><i>Lessons learned from another field: the experience of the European Coalition of People living with Obesity</i>  <b>Vicki Mooney</b>; Eurobesity, Ireland</p>
14.30-14.50	<p><i>Lifestyle interventions in Healthcare and the role of Health Insurers</i>  <b>Madelon Johannesma</b>; CZ, The Netherlands</p>
14.50-15.30	<p>Panel discussion</p>
15.30-15.50	<p>Award Ceremony: best oral presentations</p>
<u>Closing</u>	

# Accreditation

---

The **3rd European Fatty Liver Conference (EFLC2022)**, **MAASTRICHT, Netherlands, 08/06/2022-10/06/2022** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **18 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of *AMA PRA Category 1 Credits™*. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

To receive the certificate please e-mail the front desk: [f.defauwes@maastrichtuniversity.nl](mailto:f.defauwes@maastrichtuniversity.nl)

---